157 related articles for article (PubMed ID: 22903690)
1. Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
Li CI; Mirus JE; Zhang Y; Ramirez AB; Ladd JJ; Prentice RL; McIntosh MW; Hanash SM; Lampe PD
Breast Cancer Res Treat; 2012 Sep; 135(2):611-8. PubMed ID: 22903690
[TBL] [Abstract][Full Text] [Related]
2. Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study.
Buas MF; Rho JH; Chai X; Zhang Y; Lampe PD; Li CI
Breast Cancer Res Treat; 2015 Sep; 153(2):445-54. PubMed ID: 26319120
[TBL] [Abstract][Full Text] [Related]
3. Discovery and validation of breast cancer early detection biomarkers in preclinical samples.
Li CI
Horm Cancer; 2011 Apr; 2(2):125-31. PubMed ID: 21761335
[TBL] [Abstract][Full Text] [Related]
4. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
5. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
6. Triple-negative breast cancer: clinical features and patterns of recurrence.
Dent R; Trudeau M; Pritchard KI; Hanna WM; Kahn HK; Sawka CA; Lickley LA; Rawlinson E; Sun P; Narod SA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4429-34. PubMed ID: 17671126
[TBL] [Abstract][Full Text] [Related]
7. Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer.
Amon LM; Pitteri SJ; Li CI; McIntosh M; Ladd JJ; Disis M; Porter P; Wong CH; Zhang Q; Lampe P; Prentice RL; Hanash SM
Cancer Res; 2012 Apr; 72(8):1935-42. PubMed ID: 22367215
[TBL] [Abstract][Full Text] [Related]
8. Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?
Albergaria A; Ricardo S; Milanezi F; Carneiro V; Amendoeira I; Vieira D; Cameselle-Teijeiro J; Schmitt F
BMC Cancer; 2011 Jul; 11():299. PubMed ID: 21762477
[TBL] [Abstract][Full Text] [Related]
9. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
[TBL] [Abstract][Full Text] [Related]
10. Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors.
Kohler C; Radpour R; Barekati Z; Asadollahi R; Bitzer J; Wight E; Bürki N; Diesch C; Holzgreve W; Zhong XY
Mol Cancer; 2009 Nov; 8():105. PubMed ID: 19922604
[TBL] [Abstract][Full Text] [Related]
11. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer.
Phipps AI; Chlebowski RT; Prentice R; McTiernan A; Stefanick ML; Wactawski-Wende J; Kuller LH; Adams-Campbell LL; Lane D; Vitolins M; Kabat GC; Rohan TE; Li CI
Cancer Epidemiol Biomarkers Prev; 2011 Mar; 20(3):454-63. PubMed ID: 21364029
[TBL] [Abstract][Full Text] [Related]
12. DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors.
Wen YH; Brogi E; Zeng Z; Akram M; Catalano J; Paty PB; Norton L; Shia J
Am J Surg Pathol; 2012 Nov; 36(11):1700-8. PubMed ID: 22992699
[TBL] [Abstract][Full Text] [Related]
13. Detection of elevated plasma levels of epidermal growth factor receptor before breast cancer diagnosis among hormone therapy users.
Pitteri SJ; Amon LM; Busald Buson T; Zhang Y; Johnson MM; Chin A; Kennedy J; Wong CH; Zhang Q; Wang H; Lampe PD; Prentice RL; McIntosh MW; Hanash SM; Li CI
Cancer Res; 2010 Nov; 70(21):8598-606. PubMed ID: 20959476
[TBL] [Abstract][Full Text] [Related]
14. Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.
Schummer M; Thorpe J; Giraldez MD; Bergan L; Tewari M; Urban N
PLoS One; 2015; 10(11):e0142911. PubMed ID: 26565788
[TBL] [Abstract][Full Text] [Related]
15. Sonographic features of triple-negative and non-triple-negative breast cancer.
Wojcinski S; Soliman AA; Schmidt J; Makowski L; Degenhardt F; Hillemanns P
J Ultrasound Med; 2012 Oct; 31(10):1531-41. PubMed ID: 23011616
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers.
Irvin VL; Zhang Z; Simon MS; Chlebowski RT; Luoh SW; Shadyab AH; Krok-Schoen JL; Tabung FK; Qi L; Stefanick ML; Schedin P; Jindal S
JAMA Netw Open; 2020 Jun; 3(6):e207227. PubMed ID: 32602908
[TBL] [Abstract][Full Text] [Related]
17. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
18. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Cheang MC; Voduc D; Bajdik C; Leung S; McKinney S; Chia SK; Perou CM; Nielsen TO
Clin Cancer Res; 2008 Mar; 14(5):1368-76. PubMed ID: 18316557
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
[TBL] [Abstract][Full Text] [Related]
20. Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening.
Caldarella A; Puliti D; Crocetti E; Bianchi S; Vezzosi V; Apicella P; Biancalani M; Giannini A; Urso C; Zolfanelli F; Paci E
J Cancer Res Clin Oncol; 2013 Feb; 139(2):181-5. PubMed ID: 22961208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
